Mainstream

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Post ContentdawnRead More

You might also be interested in reading US, UK to collaborate on AI, quantum computing, nuclear energy development.

August 6, 2025
In Mainstream